Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36642080

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2023 Feb
First author
Dytfeld D

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Feb;24(2):118-119. doi: 10.1016/S1470-2045(22)00792-6.
    note
    Source null
    related pmid
    36642082
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Nov;20(11):735-736. doi: 10.1038/s41571-023-00801-x.
    note
    Source null
    related pmid
    37433885
    relationship
    Comment in

Authors and identifiers

  1. name
    Dytfeld D
    type
    Author
  2. name
    Wróbel T
    type
    Author
  3. name
    Jamroziak K
    type
    Author
  4. name
    Kubicki T
    type
    Author
  5. name
    Robak P
    type
    Author
  6. name
    Walter-Croneck A
    type
    Author
  7. name
    Czyż J
    type
    Author
  8. name
    Tyczyńska A
    type
    Author
  9. name
    Druzd-Sitek A
    type
    Author
  10. name
    Giannopoulos K
    type
    Author
  11. name
    Nowicki A
    type
    Author
  12. name
    Szczepaniak T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Dytfeld D
    type
    Author
  2. name
    Wróbel T
    type
    Author
  3. name
    Jamroziak K
    type
    Author
  4. name
    Kubicki T
    type
    Author
  5. name
    Robak P
    type
    Author
  6. name
    Walter-Croneck A
    type
    Author
  7. name
    Czyż J
    type
    Author
  8. name
    Tyczyńska A
    type
    Author
  9. name
    Druzd-Sitek A
    type
    Author
  10. name
    Giannopoulos K
    type
    Author
  11. name
    Nowicki A
    type
    Author
  12. name
    Szczepaniak T
    type
    Author
bibliography ids
  1. nci-bib-4bd4b3ee72721eba1f0bdc2a
book metadata
content sha256
3c7de370bb7c4d211f4c7ccdfaf599895d8f0dae19ba8c6235cb859bc90fb880
document type
citation
dois
  1. 10.1016/S1470-2045(22)00738-0
electronic publication date
display
2023 Jan 12
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:36642080
immutable id
pubmed:36642080@3c7de370bb7c4d211f4c7ccdfaf599895d8f0dae19ba8c6235cb859bc90fb880
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
2
name
The Lancet. Oncology
nlm unique id
100957246
pages
139-150
volume
24
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2023 Feb;24(2):118-119. doi: 10.1016/S1470-2045(22)00792-6.
    note
    Source null
    related pmid
    36642082
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2023 Nov;20(11):735-736. doi: 10.1038/s41571-023-00801-x.
    note
    Source null
    related pmid
    37433885
    relationship
    Comment in
outcomes validated
false
pmid
36642080
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
2746ad54ae8ac942579480029248819efc9300982a3103bec2d35733c9f74667
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Feb
precision
month
year
2023
publication types
  1. Randomized Controlled Trial
  2. Multicenter Study
  3. Clinical Trial, Phase III
  4. Journal Article
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36642080/
title
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice